Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)-echinocandin B
2. Eraxis
3. Ly 303366
4. Ly-303366
5. Ly303366
1. Eraxis
2. 166663-25-8
3. Ecalta
4. V-echinocandin
5. Ver-002
6. Ly303366
7. Ly-303366
8. Anidulafungin (ly303366)
9. Ver002
10. Chebi:55346
11. 9hlm53094i
12. D70013
13. D-70013
14. N-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
15. Anidulafungin [usan]
16. Anidulafungina
17. Anidulafungine
18. Anidulafunginum
19. Unii-9hlm53094i
20. Anidulafungin [usan:inn:ban]
21. Anidulafungin [mi]
22. Anidulafungin [inn]
23. Schembl38292
24. Anidulafungin [vandf]
25. (4r,5r)-4,5-dihydroxy-n(sup 2)-((4'-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline Cyclic (6-1)-peptide
26. Anidulafungin [mart.]
27. Anidulafungin [who-dd]
28. Chembl264241
29. Anidulafungin [ema Epar]
30. Anidulafungin [orange Book]
31. Bdbm50417554
32. Mfcd00917070
33. S4286
34. Ccg-270647
35. Cs-1824
36. Db00362
37. Ncgc00386349-01
38. Hy-13553
39. Sw222238-1
40. A13436
41. 663a258
42. J-010304
43. Q4764531
44. (4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline Cyclic (6->1)-peptide
45. Echinocandin B, 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)-
46. Echinocandin B, 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)
47. N-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
48. N-[[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1r)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
49. N-{(2r,6s,9s,11r,12r,14as,15s,16s,20s,23s,25as)-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1r)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide
Molecular Weight | 1140.2 g/mol |
---|---|
Molecular Formula | C58H73N7O17 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 17 |
Rotatable Bond Count | 14 |
Exact Mass | 1139.50629389 g/mol |
Monoisotopic Mass | 1139.50629389 g/mol |
Topological Polar Surface Area | 377 Ų |
Heavy Atom Count | 82 |
Formal Charge | 0 |
Complexity | 2150 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Eraxis |
PubMed Health | Anidulafungin (Injection) |
Drug Classes | Antifungal |
Drug Label | ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is... |
Active Ingredient | Anidulafungin |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | 100mg/vial; 50mg; 50mg/vial |
Market Status | Prescription |
Company | Pfizer; Vicuron |
2 of 2 | |
---|---|
Drug Name | Eraxis |
PubMed Health | Anidulafungin (Injection) |
Drug Classes | Antifungal |
Drug Label | ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is... |
Active Ingredient | Anidulafungin |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | 100mg/vial; 50mg; 50mg/vial |
Market Status | Prescription |
Company | Pfizer; Vicuron |
For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.
FDA Label
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes.
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
J02AX06
J - Antiinfectives for systemic use
J02 - Antimycotics for systemic use
J02A - Antimycotics for systemic use
J02AX - Other antimycotics for systemic use
J02AX06 - Anidulafungin
Route of Elimination
Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.
Volume of Distribution
30 to 50 L
Clearance
1 L/h
Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.
40-50 hours
Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
77
PharmaCompass offers a list of Anidulafungin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Anidulafungin manufacturer or Anidulafungin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Anidulafungin manufacturer or Anidulafungin supplier.
PharmaCompass also assists you with knowing the Anidulafungin API Price utilized in the formulation of products. Anidulafungin API Price is not always fixed or binding as the Anidulafungin Price is obtained through a variety of data sources. The Anidulafungin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anidulafungin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anidulafungin, including repackagers and relabelers. The FDA regulates Anidulafungin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anidulafungin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Anidulafungin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Anidulafungin supplier is an individual or a company that provides Anidulafungin active pharmaceutical ingredient (API) or Anidulafungin finished formulations upon request. The Anidulafungin suppliers may include Anidulafungin API manufacturers, exporters, distributors and traders.
click here to find a list of Anidulafungin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Anidulafungin DMF (Drug Master File) is a document detailing the whole manufacturing process of Anidulafungin active pharmaceutical ingredient (API) in detail. Different forms of Anidulafungin DMFs exist exist since differing nations have different regulations, such as Anidulafungin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Anidulafungin DMF submitted to regulatory agencies in the US is known as a USDMF. Anidulafungin USDMF includes data on Anidulafungin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Anidulafungin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Anidulafungin suppliers with USDMF on PharmaCompass.
A Anidulafungin written confirmation (Anidulafungin WC) is an official document issued by a regulatory agency to a Anidulafungin manufacturer, verifying that the manufacturing facility of a Anidulafungin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Anidulafungin APIs or Anidulafungin finished pharmaceutical products to another nation, regulatory agencies frequently require a Anidulafungin WC (written confirmation) as part of the regulatory process.
click here to find a list of Anidulafungin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Anidulafungin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Anidulafungin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Anidulafungin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Anidulafungin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Anidulafungin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Anidulafungin suppliers with NDC on PharmaCompass.
Anidulafungin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anidulafungin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anidulafungin GMP manufacturer or Anidulafungin GMP API supplier for your needs.
A Anidulafungin CoA (Certificate of Analysis) is a formal document that attests to Anidulafungin's compliance with Anidulafungin specifications and serves as a tool for batch-level quality control.
Anidulafungin CoA mostly includes findings from lab analyses of a specific batch. For each Anidulafungin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anidulafungin may be tested according to a variety of international standards, such as European Pharmacopoeia (Anidulafungin EP), Anidulafungin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anidulafungin USP).